Form 4 Filing for BELITE BIO, INC.

Lin Yu-Hsin, Chief Executive Officer and Director of BELITE BIO, INC., reported a transaction on April 21, 2026. This transaction involved the acquisition of 10,000 ordinary shares. The shares were acquired through the vesting of restricted stock units (RSUs) that were initially granted on September 15, 2025. The vesting occurred because certain performance criteria were met. The reported transaction code is "J", and the acquisition code is "A". The price per share was $0.00, indicating that this was likely a performance-based award rather than a market purchase. Following this transaction, Lin Yu-Hsin now owns 182,949 ordinary shares of BELITE BIO, INC. The filing was signed on April 23, 2026.